Beam Therapeutics Inc.NASDAQ: BEAM

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

· Issued by Beam Therapeutics Inc.
Watch Beam Therapeutics explain itBeam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call · Replay · Feb 24

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to